APT Therapeutics addresses this challenge through an enzyme-based therapeutic approach that targets platelet activation differently from conventional drugs. Its lead candidate, APT102, works by metabolically depleting extracellular ADP and ATP, which are key drivers of platelet activation.
“APT102 is more efficacious as it metabolically depletes both extracellular ADP and ATP,” says Ridong Chen, president.
Redefining the Balance between Efficacy and Safety
A central limitation of existing therapies is their mechanism of action. Current P2Y12 inhibitors block a single receptor pathway, which can lead to increased bleeding risk and delayed onset when administered orally.
APT102 introduces a broader mechanism by targeting multiple platelet activation pathways simultaneously, while maintaining a more favorable safety profile. Unlike receptor-blocking drugs, it does not compromise platelet integrity but instead reduces the availability of activating molecules.
Another key distinction lies in its delivery method. As an intravenous enzyme, APT102 becomes effective within minutes, addressing the critical need for immediate intervention in heart attack scenarios. This rapid onset supports improved blood flow restoration during early treatment stages.
Addressing Time-Sensitive Clinical Challenges
Patients experiencing heart attacks face multiple risks, including clot formation, delayed treatment response, and reperfusion injury following intervention. Existing therapies are often limited by slow absorption and dose-related safety concerns.
APT Therapeutics focuses on improving both speed and effectiveness of treatment. By enabling faster antithrombotic action, APT102 supports earlier restoration of blood flow. Its mechanism also contributes to cardioprotection through localized generation of adenosine in cardiac tissue.
This localized effect distinguishes it from therapies that increase systemic adenosine levels. By concentrating cardioprotective activity at the site of injury, the approach aims to reduce tissue damage associated with reperfusion.
Demonstrating Impact through Scientific Development
APT102 is built on foundational research into CD39, an enzyme involved in regulating platelet activation. Through protein engineering, APT Therapeutics developed a modified enzyme with enhanced activity and improved manufacturability.
-
APT102 is more efficacious as it metabolically depletes both extracellular ADP and ATP.”
The development process involved collaboration with leading cardiology experts and extensive preclinical testing aligned with clinical endpoints. This approach ensured that laboratory findings translated effectively into potential clinical applications.
In preclinical studies, APT102 demonstrated significant reductions in infarct size and improved cardiac protection compared to existing therapies. Combination use with ticagrelor further enhanced outcomes without increasing bleeding risk.
Clinical evaluation has also supported its safety profile. In a Phase 1 trial involving healthy subjects, the therapy showed no clinically relevant safety concerns, providing a foundation for further development in larger trials.
Looking ahead, reperfusion injury and subsequent heart failure remain significant unmet needs in cardiovascular care. Current treatment options have yet to fully address these challenges, despite decades of research.
APT Therapeutics is positioning APT102 to address this gap by enabling continuous local generation of cardioprotective adenosine. This approach aims to improve outcomes following revascularization procedures and reduce long-term complications.
With plans to advance into Phase 2 trials, the company is focused on translating its preclinical and early clinical results into broader therapeutic applications. By combining rapid antithrombotic action with cardioprotective effects, APT Therapeutics is advancing a new direction in the treatment of acute myocardial infarction.
